Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Abstract Anti‐angiogenic drugs are approved for the treatment of several cancer types, generally in the inoperable locally advanced or metastatic setting and in combination with other anti‐cancer agents. Recent clinical studies also suggest that anti‐angiogenic drugs can be useful in the pre‐operati...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2014-11-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201404640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849343364298702848 |
|---|---|
| author | Daniela Biziato Michele De Palma |
| author_facet | Daniela Biziato Michele De Palma |
| author_sort | Daniela Biziato |
| collection | DOAJ |
| description | Abstract Anti‐angiogenic drugs are approved for the treatment of several cancer types, generally in the inoperable locally advanced or metastatic setting and in combination with other anti‐cancer agents. Recent clinical studies also suggest that anti‐angiogenic drugs can be useful in the pre‐operative (neoadjuvant) setting, by facilitating the shrinkage of the primary tumour and its surgical resection. However, the effects of neoadjuvant anti‐angiogenic therapy on the ability of tumours to form distant metastases are unclear. In this issue of EMBO Molecular Medicine, Ebos et al (2014) present carefully performed pre‐clinical studies in mice that analyse the effects of pre‐operative anti‐angiogenic therapy on tumour metastasis and survival. |
| format | Article |
| id | doaj-art-05d7a709f88f4e7bab459cdbb758f6d5 |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2014-11-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-05d7a709f88f4e7bab459cdbb758f6d52025-08-20T03:43:01ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842014-11-016121515151710.15252/emmm.201404640Assessing metastasis risk after pre‐operative anti‐angiogenic therapyDaniela Biziato0Michele De Palma1The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL)The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL)Abstract Anti‐angiogenic drugs are approved for the treatment of several cancer types, generally in the inoperable locally advanced or metastatic setting and in combination with other anti‐cancer agents. Recent clinical studies also suggest that anti‐angiogenic drugs can be useful in the pre‐operative (neoadjuvant) setting, by facilitating the shrinkage of the primary tumour and its surgical resection. However, the effects of neoadjuvant anti‐angiogenic therapy on the ability of tumours to form distant metastases are unclear. In this issue of EMBO Molecular Medicine, Ebos et al (2014) present carefully performed pre‐clinical studies in mice that analyse the effects of pre‐operative anti‐angiogenic therapy on tumour metastasis and survival.https://doi.org/10.15252/emmm.201404640 |
| spellingShingle | Daniela Biziato Michele De Palma Assessing metastasis risk after pre‐operative anti‐angiogenic therapy EMBO Molecular Medicine |
| title | Assessing metastasis risk after pre‐operative anti‐angiogenic therapy |
| title_full | Assessing metastasis risk after pre‐operative anti‐angiogenic therapy |
| title_fullStr | Assessing metastasis risk after pre‐operative anti‐angiogenic therapy |
| title_full_unstemmed | Assessing metastasis risk after pre‐operative anti‐angiogenic therapy |
| title_short | Assessing metastasis risk after pre‐operative anti‐angiogenic therapy |
| title_sort | assessing metastasis risk after pre operative anti angiogenic therapy |
| url | https://doi.org/10.15252/emmm.201404640 |
| work_keys_str_mv | AT danielabiziato assessingmetastasisriskafterpreoperativeantiangiogenictherapy AT micheledepalma assessingmetastasisriskafterpreoperativeantiangiogenictherapy |